Navigation Links
QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
Date:7/29/2009

ANN ARBOR, Mich., July 29 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3 studies. QuatRx intends to use these results in support of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2010 seeking approval for Ophena(TM), a new SERM (selective estrogen receptor modulator) for the treatment of the symptoms of vulvovaginal atrophy. Ophena(TM) is the only non-estrogen therapy currently in late-stage development for the treatment of vaginal symptoms associated with menopause.

"We are delighted with the progress in our Phase 3 program of Ophena(TM), which provides further evidence of the potential of Ophena(TM) as a first-in-class non-estrogen drug for the treatment of vaginal atrophy, a highly prevalent and symptomatic condition" said Robert L. Zerbe, M.D., Chief Executive Officer of QuatRx. "These new efficacy data confirm results seen in our first phase 3 pivotal study and are an important milestone towards our planned NDA submission."

This second Phase 3 study of Ophena(TM) is a randomized, double-blind, placebo-controlled trial of 919 patients with vulvovaginal atrophy conducted at 116 sites in the United States. Patients were stratified into two cohorts based on their most bothersome moderate to severe vaginal atrophy symptom - either vaginal dryness or dyspareunia (sexual pain). The results announced today focus on the cohort of 314 patients from this study identifying vaginal dryness as their m
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
2. HCA Announces Offering of $750 Million Senior Secured First Lien Notes
3. Mylan Announces Enhancements to Executive Management Team
4. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
5. ONRAD Announces Newly Bundled Services for a Single Package Price
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
7. Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
8. Zix Corporation Reports Another Record-High Revenue Quarter as Company Announces Second Quarter 2009 Financial Results
9. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
10. NephCure Foundation Announces Research Grant Program Recipients
11. TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... 01, 2014 NoteSwift Inc., announced today ... 10.0, 12.1 and 13.0. NoteSwift is the bridge between ... to navigate and document clinical information at the point ... creating a patient note by more than half – ... major pain points providers state impedes EHR use according ...
(Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... October is national Breast Cancer Awareness ... plans while raising money for breast cancer research. Pelican ... Month in the effort to find a cure. ... importance of having access to clean, healthy water. Research ... to certain forms of cancer. , The Problem ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... Imaging (BSGI) has,been proven to be a highly ... carcinoma (ILC), a difficult to diagnose breast cancer. ... see lesions independent of,tissue density and discover very ... magnetic resonance imaging (MRI), BSGI has the,greatest sensitivity ...
... UNH ) is giving Pennsylvania children the ... childhood obesity, designing programs to,address it and implementing ... UnitedHealth HEROES is a ... working through educators and youth,leaders, to create and ...
... Money may be better spent in other areas, experts say ... teams, created to prevent cardiac arrest and deaths in critically ... finds. , "Many hospitals have implemented these teams over the ... cardiologist at the Mid America Heart Institute in Kansas City, ...
... name for the project formerly known as “Clinical Document Architecture for Common ... standards developed by the project and submitted to Health Level Seven (HL7) ... ... 2, 2008 -- "Our group has been working with many partners ...
... of Engineering has led to significant improvements in turnover ... hospitals, allowing "many more hours of daytime surgery per ... work will be expanded to include three more hospitals. ... of Industrial and Systems Engineering began work in January, ...
... Thursday December 4th Governor Howard Dean will deliver the Keynote ... the Pulse of Health IT: A Critical Review of Progress ... and Beyond." , , (Logo: ... The Keynote speech will begin at 4:30 p.m. For more ...
Cached Medicine News:Health News:Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma 2Health News:UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 2Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 4Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 5Health News:Operations engineering for more efficient operating rooms 2Health News:Operations engineering for more efficient operating rooms 3
(Date:10/1/2014)... -- NeuroCall, Inc., ("NeuroCall") announced today that it recently ... services. Dr. Ricardo Garcia-Rivera , Founder and Chief ... that our quality of service has been recognized by ... support and continuity of care to patients of our ... United States ." NeuroCall currently ...
(Date:10/1/2014)... LOUIS , Oct. 1, 2014  Express Scripts ... two nationally available 2015 Express Scripts Medicare ® ... pharmacy network featuring Walgreens (NYSE: WAG ) ... more value, choice and clinical support  for their Medicare ... Express Scripts Medicare Value or Choice ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... ... Symposium, SAN ... and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, announced new ... AACR-NCI-EORTC Symposium. "These studies show potential progress toward identifying specific,tumor ...
... and Effective Symptom Control, BOSTON, Oct. ... TSX: SHQ), the global specialty biopharmaceutical company, ... DAYTRANA(TM) (methylphenidate,transdermal system), the Attention Deficit Hyperactivity ... ADHD tolerability,and symptom control improvement in children ...
Cached Medicine Technology:Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5
... of thumb motion can be difficult for ... persons with spinal cord injuries and for ... cerebral palsy or other motor or coordination ... thumb for control and coordination. Soft foam-lined ...
... weight and strong, the ThumSaver CMC Short lessens ... the CMC and/or MP joints of the thumb. ... and full IP joint motion for function. Includes ... Skiers thumb, and for rest due to repetitive ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
... orthosis is designed to comfortably restrict motion ... the hand in a neutral position. It ... thermoplastic whose unique characteristics offer durable performance ... rigid cast-like immobilization of the wrist, hand, ...
Medicine Products: